R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model

Behavioural Pharmacology

Volumn 14, Issue 5-6, 2003, Pages 465-470

  Sánchez, Connie ^a   Gruca, P ^b   Papp, M ^b  

^a H LUNDBECK A S   (Denmark)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Chronic mild stress; Citalopram; Depression; Escitalopram; Rat

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DEPRESSION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; MALE; NONHUMAN; STRESS; TREATMENT OUTCOME;

ANIMALS; CITALOPRAM; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; MALE; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS; STEREOISOMERISM; STRESS, PSYCHOLOGICAL;

EID: 0141534297     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. 1A receptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopram. Naunyn Schmiedeberg's Arch Pharmacol 352:157-165.
2. Artigas F, Perez V, Alvarez E (1994). Pindolol induces rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 51:248-251.
3. 1A antagonists. Trends Neuropharm Sci 19:378-383.
4. Blier P, de Montigny C (1997). Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15:220-226.
5. 1A receptors induces rapid antidepressant response. Neuropsychopharmacology 16:333-338.
6. Brøsen K, Naranjo CA (2001). Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 11:275-283.
7. Burke WJ, Gergel I, Bose A (2002). Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63:331-336.
8. Foglia JP, Pollock BG, Kirshner MA, Rosen J, Sweet R, Mulsant B (1997). Plasma levels of citalopram enantiomers and metabolites in elderly patients. Psychopharmacol Bull 33:109-112.
9. Gambarana C, Scheggi S, Tagliamonte A, Tolu P, De Montis MG (2001). Animal models for the study of antidepressant activity. Brain Res Protoc 7:11-20.
10. Gorman J, Korotzer A, Su G (2002). Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectrums 7:40-44.
11. Hyttel J, Bøgesø KP, Perregaard J, Sánchez C (1992). The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J Neur Transm 8:157-160.
12. Kugelberg FC, Apelqvist G, Carlsson B, Ahlner J, Bengtsson F (2001). In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats. Br J Pharmacol 132:1683-1690.
13. Marona-Lewicka D, Nichols DE (1997). The effect of selective serotonin releasing agents in the chronic mild stress model of depression in rats. Stress 2:91-100.
14. Montgomery SA, Loft H, Sánchez C, Reines EH, Papp M (2001). Escitalopram (S-enanfiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol 88:282-286.
15. Mørk A, Kreilgaard M, Sánchez C (2003). The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 45:167-173.
16. Olesen OV, Linnet K (1999). Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology 59:298-309.
17. Owens MJ, Knight DL, Nemeroff CB (2001). Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50:345-350.
18. Papp M, Moryl E (1994). Antidepressant activity of non-competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol 263:1-7.
19. Papp M, Moryl E, Willner P (1996). Pharmacological validation of the chronic mild stress model of depression. Eur J Pharmacol 296:129-136.
20. 3H]paroxetine binding to platelet and neuronal membranes. Eur J Pharmacol 119:1-8.
21. 3H]citalopram binding to the 5-HT transporter from brain and platelets. Eur J Pharmacol 206:243-250.
22. 1A receptor ligands in the chronic mild stress model of depression. Neuropharmacology 34:1305-1310.
23. Reines EH, Loft H, Lepola U (2002). Escitalopram is efficacious and well tolerated in the treatment of depression in primary care. Eur Neuropsychopharmacol 12(suppl 3):S254.
24. Sánchez C (2003). R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model. Eur J Pharmacol 464:155-158.
25. 2 ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression. Behav Pharmacol 11:117-124.
26. Sánchez C, Bergqvist PBF, Brennum LT, Gupta S, Hogg S, Larsen AK, Wiborg O (2003). Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent antidepressant and anxiolytic activities. Psychopharmacology 167:353-362.
27. Sidhu J, Priskorn M, Poulsen M, Segonzac A, Grollier G, Larsen F (1997). Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality 9:686-692.
28. Sluzewska A, Szczawinska K (1996). The effects of pindolol addition to fluvoxamine and buspirone in chronic mild stress model of depression. Behav Pharmacol 7(suppl 1):105.
29. Wade A, Lemming O, Bang Hedegaard K (2002). Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 11:95-102.
30. Wiborg O, Sánchez C (2002). Escitalopram: A comparative in vitro study of 5-HT uptake inhibition and binding in a COS-1 cell line expressing the human 5-HT transporter. Eur Neuropsychopharmacol 12(suppl 3):S229.
31. Willner P (1997). Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology 134:319-329.
32. Willner P, Mitchell PJ (2002). The validity of animal models of predisposition to depression. Behav Pharmacol 13:169-188.
33. Zheng Z, Jamour M, Klotz U (2000). Stereoselective HPLC-assay for citalopram and its metabolites. Ther Drug Monit 22:219-224.